ABSTRACT
Vascular smooth muscle cells (VSMCs) exhibit a high degree of plasticity when they undergo the progression from a normal to a disease condition, which makes them a potential target for evaluating early markers and for the development of new therapies. Purinergic signalling plays a key role in vascular tonus control, ATP being an inductor of vasoconstriction, whereas adenosine mediates a vasodilation effect antagonising the ATP actions. The control of extracellular ATP and adenosine levels is done by ectonucleotidases, which represent a potential target to be evaluated in the progression of cardiovascular diseases. In this study, we analysed the basal activity and expression of the ectonucleotidases in aortic rat VSMCs, and we further performed in silico analysis to determine the expression of those enzymes in conditions that mimicked vascular diseases. Cultured in vitro VSMCs showed a prominent expression of Entpd1 followed by Entpd2 and Nt5e (CD73) and very low levels of Entpd3. Slightly faster AMP hydrolysis was observed when compared to ATP and ADP nucleotides. In silico analysis showed that the ectonucleotidases were modulated after induction of conditions that can lead to vascular diseases such as, hypertensive and hypotensive mice models (Nt5e); exposition to high-fat (Entpd1 and Entpd2) or high-phosphate (Nt5e) diet; mechanical stretch (Entpd1, Entpd2 and Nt5e); and myocardial infarction (Entpd1). Our data show that VSMCs are able to efficiently metabolise the extracellular nucleotides generating adenosine. The modulation of Entpd1, Entdp2 and Nt5e in vascular diseases suggests these ectoenzymes as potential targets or markers to be investigated in future studies.
Subject(s)
5'-Nucleotidase/metabolism , Adenosine Triphosphatases/metabolism , Antigens, CD/metabolism , Apyrase/metabolism , Muscle, Smooth, Vascular/pathology , Vascular Diseases/physiopathology , Adenosine/metabolism , Adenosine Diphosphate/metabolism , Adenosine Triphosphate/metabolism , Animals , Aorta/cytology , Computer Simulation , GPI-Linked Proteins/metabolism , Mice , Muscle, Smooth, Vascular/enzymology , Nucleotides/metabolism , Rats , Rats, Wistar , Vascular Diseases/enzymologyABSTRACT
Abstract Background: Despite increase in survival of human immunodeficiency virus (HIV) patients due to highly active antiretroviral therapy, non-infectious complications are still prevalent such as presentation of lung vasculopathy, even in asymptomatic patients. Endothelial nitric oxide synthase (eNOS) is necessary to produce nitric oxide that causes pulmonary endothelial vasodilation. Participation of this protein in the pulmonary circulation in HIV patients has not been elucidated. This work studied the presence and expression of eNOS in pulmonary complex vascular lesions associated with HIV (PCVL/HIV). Methods: In lung tissues from patients who died from complications of HIV, we used immunohistochemistry and immune chemiluminescence (imageJ) to determine the different degrees of expression of eNOS in PCVL-HIV in comparison with non-PCVL/HIV. Reagents used were anti-eNOS and an automated system. All data are presented as mean and standard deviation. Differences were analyzed with Wilcoxon; p < 0.05 was accepted as statistically significant. Results: In 57 tissues, the histological evidence of pulmonary vasculopathy was showed as different types (proliferative, obliterative, and plexiform) and severe presentation of vasculopathy than non-PCVL/HIV. A statistically significant decrease of eNOS was observed in all PCVL/HIV tissue samples. Conclusion: eNOS has a relevant role in the pathogenesis of pulmonary vasculopathy in acquired immunodeficiency syndrome patients. It is necessary to determine in the future the participation of eNOS and other mechanisms involved in PCVL/HIV.
Resumen Antecedentes: A pesar del incremento en la sobrevivencia del paciente con virus de inmunodeficiencia humana (VIH) debido al uso del tratamiento antiretroviral altamente efectivo, las complicaciones no infecciosas siguen ocasionando vasculopatía pulmonar, aun en pacientes asintomáticos. La óxido nítrico sintetasa (ONSe) es necesaria para la producción de óxido nítrico la cual provoca vasodilatación pulmonar. La participación de esta proteína en la circulación pulmonar en los pacientes con VIH aún no se ha dilucidado. Este trabajo estudia la presencia y la expresión de ONSe en las lesiones vasculares pulmonares complejas asociadas al VIH (LVPC/VIH). Métodos: En tejidos pulmonares de pacientes que fallecieron por complicaciones del VIH, se utilizó inmunohistoquímica e inmunoquimioluminescencia (imageJ) para determinar los diferentes grados de expresión de la ONSe en LVPC/VIH. Los reactivos utilizados son anti-ONSe en sistema automatizado. Todos los datos son presentados en media y desviación estándar. Las diferencias son analizadas con la prueba de Wilcoxon; se aceptó como estadísticamente significativa una p < 0.05. Resultados: En 57 pacientes, la histología de la vasculopatía pulmonar mostró diferentes tipos (proliferativo, obliterativo y plexiforme) además de varias presentaciones de vasculopatía en tejidos no-LVPC/VIH. Se observó diferencia estadística en la disminución de ONSe en todos los tejidos LVPC/VIH. Conclusiones: La ONSe tiene un papel relevante en la patogénesis de la vasculopatía pulmonar en el VIH. Es necesario determinar en el futuro la participación de ONSe y otros mecanismos involucrados en LVPC/VIH.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Young Adult , Vascular Diseases/physiopathology , HIV Infections/complications , Nitric Oxide Synthase Type III/metabolism , Nitric Oxide/metabolism , Pulmonary Artery/physiopathology , Vascular Diseases/enzymology , Vascular Diseases/virology , Severity of Illness IndexABSTRACT
Background: Despite increase in survival of human immunodeficiency virus (HIV) patients due to highly active antiretroviral therapy, non-infectious complications are still prevalent such as presentation of lung vasculopathy, even in asymptomatic patients. Endothelial nitric oxide synthase (eNOS) is necessary to produce nitric oxide that causes pulmonary endothelial vasodilation. Participation of this protein in the pulmonary circulation in HIV patients has not been elucidated. This work studied the presence and expression of eNOS in pulmonary complex vascular lesions associated with HIV (PCVL/HIV). Methods: In lung tissues from patients who died from complications of HIV, we used immunohistochemistry and immune chemiluminescence (imageJ) to determine the different degrees of expression of eNOS in PCVL-HIV in comparison with non-PCVL/HIV. Reagents used were anti-eNOS and an automated system. All data are presented as mean and standard deviation. Differences were analyzed with Wilcoxon; p < 0.05 was accepted as statistically significant. Results: In 57 tissues, the histological evidence of pulmonary vasculopathy was showed as different types (proliferative, obliterative, and plexiform) and severe presentation of vasculopathy than non-PCVL/HIV. A statistically significant decrease of eNOS was observed in all PCVL/HIV tissue samples. Conclusion: eNOS has a relevant role in the pathogenesis of pulmonary vasculopathy in acquired immunodeficiency syndrome patients. It is necessary to determine in the future the participation of eNOS and other mechanisms involved in PCVL/HIV.
Antecedentes: A pesar del incremento en la sobrevivencia del paciente con virus de inmunodeficiencia humana (VIH) debido al uso del tratamiento antiretroviral altamente efectivo, las complicaciones no infecciosas siguen ocasionando vasculopatía pulmonar, aun en pacientes asintomáticos. La óxido nítrico sintetasa (ONSe) es necesaria para la producción de óxido nítrico la cual provoca vasodilatación pulmonar. La participación de esta proteína en la circulación pulmonar en los pacientes con VIH aún no se ha dilucidado. Este trabajo estudia la presencia y la expresión de ONSe en las lesiones vasculares pulmonares complejas asociadas al VIH (LVPC/VIH). Métodos: En tejidos pulmonares de pacientes que fallecieron por complicaciones del VIH, se utilizó inmunohistoquímica e inmunoquimioluminescencia (imageJ) para determinar los diferentes grados de expresión de la ONSe en LVPC/VIH. Los reactivos utilizados son anti-ONSe en sistema automatizado. Todos los datos son presentados en media y desviación estándar. Las diferencias son analizadas con la prueba de Wilcoxon; se aceptó como estadísticamente significativa una p < 0.05. Resultados: En 57 pacientes, la histología de la vasculopatía pulmonar mostró diferentes tipos (proliferativo, obliterativo y plexiforme) además de varias presentaciones de vasculopatía en tejidos no-LVPC/VIH. Se observó diferencia estadística en la disminución de ONSe en todos los tejidos LVPC/VIH. Conclusiones: La ONSe tiene un papel relevante en la patogénesis de la vasculopatía pulmonar en el VIH. Es necesario determinar en el futuro la participación de ONSe y otros mecanismos involucrados en LVPC/VIH.
Subject(s)
HIV Infections/complications , Nitric Oxide Synthase Type III/metabolism , Nitric Oxide/metabolism , Vascular Diseases/physiopathology , Adult , Female , Humans , Male , Middle Aged , Pulmonary Artery/physiopathology , Severity of Illness Index , Vascular Diseases/enzymology , Vascular Diseases/virology , Young AdultABSTRACT
Liver cirrhosis is associated with a wide range of cardiovascular abnormalities including hyperdynamic circulation and cirrhotic cardiomyopathy. The pathogenic mechanisms of these cardiovascular changes are multifactorial and include vascular dysregulations. AIM: The present study tested the hypothesis that the systemic vascular hyporesponsiveness in thioacetamide (TAA)-induced liver injury model is dependent on nitric oxide (NO) and cyclooxygenase (COX) derivatives. MAIN METHODS: Wistar rats were treated with TAA for eight weeks to induce liver injury. KEY FINDINGS: The maximal contractile response in concentration-effect curves to phenylephrine was decreased in aorta from TAA-treated rats, but no differences were found in aorta without endothelium, suggesting an endothelium-dependent mechanism in decreased contractile response. There was no difference in the contractile response with and without L-NAME (N(ω)-nitro-l-arginine methyl ester) in rats with liver injury, showing that the TAA treatment impairs NO synthesis. Pre-incubation of the aorta with indomethacin, a COX-inhibitor, normalized the reduced contractile response to phenylephrine in arteries from TAA group. Also, COX-2 and iNOS (inducible nitric oxide syntase) protein expression was increased in aorta from TAA group compared to control group. Animals submitted to TAA treatment had a reduction in systolic blood pressure. Our findings demonstrated that liver injury induced by TAA caused a decrease in aortic contractile response by a COX-dependent mechanism but not by NO release. Also, it was demonstrated an inflammatory process in the aorta of TAA-treated rats by increased expression of COX-2 and iNOS. SIGNIFICANCE: Therefore, there is an essential contribution of COX-2 activation in extra-hepatic vascular dysfunction and inflammation present in cirrhosis induced by TAA.
Subject(s)
Aorta, Thoracic/pathology , Chemical and Drug Induced Liver Injury/physiopathology , Cyclooxygenase 2/metabolism , Endothelium, Vascular/pathology , Thioacetamide/toxicity , Vascular Diseases/etiology , Animals , Aorta, Thoracic/enzymology , Blood Pressure , Chemical and Drug Induced Liver Injury/etiology , Endothelium, Vascular/enzymology , Male , Nitric Oxide/metabolism , Rats , Rats, Wistar , Vascular Diseases/enzymologyABSTRACT
UNLABELLED: The substitution of cytosine (C) by thymine (T) at nucleotide 677 of the methylenetetrahydrofolate reductase (MTHFR) gene, which converts an alanine to a valine residue, is a frequent polymorphism with reduced specific activity, associated with moderate increase in plasma homocysteine levels (tHcy) and risk of vascular diseases. OBJECTIVES: This study was designed to investigate an association of this polymorphism with tHcy and vascular risk factors. METHODS: We used a cross-sectional study on subjects affiliated to three health centers from Buenos Aires city. The diagnosis of hypertension was ascertained by patients' clinical history. Only subjects under long-term antihypertensive treatment were included. RESULTS: Samples from 138 physically active individuals (44 men and 94 women) randomly selected were included. The mean tHcy was significantly higher amongst hypertensives (HT) than normotensives (NT). The risk of hypertension was compared in subjects with CC genotype and the combined number of subjects with at least one T allele (CT/TT). There was no significant difference regarding the risk of hypertension between NT and HT groups in the overall sample. However, as obesity is considered a risk factor for hypertension development, when only HT (n = 29) and NT (n = 66) subjects with body mass index below 30 kg/m(2) (BMI<30) were compared, subjects bearing CT/TT presented a significantly higher risk of hypertension than those bearing the CC genotype and significantly higher concentration of tHcy. CONCLUSIONS: Our results indicate an association of hyper-tHcy and MTHFR C677T mutation with hypertension. MTHFR C677T mutation may contribute to hypertension or affect the development of hypertension through hyperhomocysteinemia.
Subject(s)
Homocysteine/blood , Hypertension/etiology , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Polymorphism, Single Nucleotide , Adolescent , Adult , Aged , Alleles , Argentina , Base Sequence , Cross-Sectional Studies , DNA Primers/genetics , Female , Gene Frequency , Genotype , Humans , Hyperhomocysteinemia/complications , Hypertension/blood , Hypertension/enzymology , Hypertension/genetics , Male , Middle Aged , Risk Factors , Vascular Diseases/blood , Vascular Diseases/enzymology , Vascular Diseases/etiology , Vascular Diseases/genetics , Young AdultABSTRACT
La determinación de los niveles de homocisteína plasmática total se ha convertido en un estudio de gran utilidad debido a que los valores moderadamente elevados de homocisteína circulantes pueden causar aterosclerosis y obstrucción de las arterias coronarias. Se sabe que son varios los factores que causan el aumento de homocisteína plasmática; éstos incluyen afecciones metabólicas hereditarias, estado nutricional y el tratamiento con ciertos fármacos. Los posibles mecanismos por los cuales los niveles elevados de homocisteína causan afecciones vasculares incluyen efectos sobre las plaquetas, los factores de coagulación y el endotelio. Las lesiones ateroscleróticas y la trombosis relacionadas con la hiperhomocisteinemia podrían ser prevenidas con una dieta rica en vitaminas, aunque esto hasta el presente no ha sido comprobado (AU)
Subject(s)
Homocysteine/metabolism , Methionine/metabolism , Vascular Diseases/enzymology , Vitamins/administration & dosage , Vitamins/therapeutic use , Risk Factors , Thrombosis/prevention & controlABSTRACT
La determinación de los niveles de homocisteína plasmática total se ha convertido en un estudio de gran utilidad debido a que los valores moderadamente elevados de homocisteína circulantes pueden causar aterosclerosis y obstrucción de las arterias coronarias. Se sabe que son varios los factores que causan el aumento de homocisteína plasmática; éstos incluyen afecciones metabólicas hereditarias, estado nutricional y el tratamiento con ciertos fármacos. Los posibles mecanismos por los cuales los niveles elevados de homocisteína causan afecciones vasculares incluyen efectos sobre las plaquetas, los factores de coagulación y el endotelio. Las lesiones ateroscleróticas y la trombosis relacionadas con la hiperhomocisteinemia podrían ser prevenidas con una dieta rica en vitaminas, aunque esto hasta el presente no ha sido comprobado
Subject(s)
Homocysteine/metabolism , Methionine/metabolism , Vascular Diseases/enzymology , Risk Factors , Thrombosis , Vitamins , Vitamins/therapeutic useABSTRACT
A study of several elements of the antioxidative system: Cu-Zn superoxide dismutase (SOD), catalase (CAT), glutathione system (GLU), chemiluminescence (CHE), and antioxidant capacity (AOX), was conducted in 20 demented probable Alzheimer's (DAT), and 15 vascular demented (VD) patients, 19 control (C) subjects, and 11 relatives (F) of one DAT patient. A significant association was found between the variables of the antioxidant system, measured in blood samples, and the neurological pathologies VD and DAT: Kruskal-Wallis test; p = 0.0006 (p = 0.014 when the analysis did not include SOD). This demonstrated that VD and DAT diseases are accompanied by oxidative disorders. The VD and DAT diseases are differentially distinguishable by changes in blood profiles. A graphical method for classification, the Principal Components Analysis (PCA), distinguished between demented and non-demented subjects on the basis of their laboratory variables. A numerical method, Discriminant Functions (DF), constructed to separate the clinical groups on the basis of the same variables, obtained relatively high percentages of success: 92% of demented were detected against healthy subjects; of the latter 82% have been correctly identified as non-demented. Discrimination between VD and DAT patients was achieved for 100% of VD and 86% of DAT patients. DF were similarly successful in detecting the healthy condition of DAT relatives. Possible different mechanisms involved in H2O2 elimination in DAT and VD patients are proposed, where CAT is the responsible enzyme of this reaction in DAT patients, while in VD this function would be achieved mainly through the action of GLU. It seems that SOD levels are stable, at least, within one year. Variations appear to be linked with clinical changes.